IDENTIFICATION DETAILS
|
Name : |
RAJASTHAN ANTIBIOTICS LIMITED (w.e.f. 06.03.1989) |
|
|
|
|
Formerly Known
As : |
CEPHAM MEDICAL LIMITED CEPHAM MEDICAL LEASING LIMITED |
|
|
|
|
Country : |
|
|
|
|
|
Financials (as
on) : |
31.03.2013 |
|
|
|
|
TAN No.: [Tax Deduction &
Collection Account No.] |
DELR11698B |
|
|
|
|
PAN No.: [Permanent Account No.] |
AAACR0925L |
|
|
|
|
Legal Form : |
A Closely Held Public Limited Liability Company |
|
|
|
|
No. of Employees
: |
Not Divulged |
BUSINESS DETAILS
|
Line of Business : |
Manufacturing of Bulk Drugs and also Manufacturing cum Trading of
Herbal Products. |
||||
|
|
|
||||
|
Products/ Services : |
|
GENERAL INFORMATION
|
No. of Employees : |
Not Divulged |
|||||||||||||||||||||||||||
|
|
|
|||||||||||||||||||||||||||
|
Bankers : |
·
State Bank of Bikaner & Jaipur, 16/67-68, ·
State Bank of · State Bank of Patiala, 2nd Floor, Chandralok Building, 36,Janpath, New Delhi - 110001, India · Industrial Finance Corporation of India, Bank of Baroda Building, 16,Sansad Marg, New Delhi - 110001, India · IFCI Limited, IFCI Tower, Nehru Place, New Delhi - 110019, India · IDBI Limited, Jeevan Nidhi Building, LIC Complex, Ambedkar Circle, Bhawani Singh Road, Jaipur - 302001, Rajasthan, India ·
Industrial Development Bank of India, IDBI
Towers, Cuffe Parade, Colaba, Bombay - 400005, Maharashtra, India |
|||||||||||||||||||||||||||
|
|
|
|||||||||||||||||||||||||||
|
Facilities : |
|
|
|
|
|
Banking
Relations : |
-- |
|
|
|
|
Auditors : |
|
|
Name : |
J P Chawla and Company Chartered Accountants |
|
Address : |
43, Backlane, Daryaganj, New Delhi – 110002, India |
|
Income-tax
PAN of auditor or auditor's firm : |
AAAFJ2213J |
|
|
|
|
Enterprises which are owned, or have significant influence of or are
partners with Key management personnel and their relatives : |
· Quad Lifesciences Private Limited [U24232CH2012PTC033660] · Cebon India Limited [U24232HR1988PLC030362] · Cepham Milk Specialities Limited [L15203PB1991PLC019162] · Cepham Organics Limited [U24239DL1984PLC018500] · Cepham Laboratories Limited [U24230DL1977PLC008694] · Cepham Agencies Private Limited [U24232DL1983PTC015187] · Revivaa Biotech Private Limited [U52100DL2010PTC201633] · Arviv Lifesciences Private Limited [U52100DL2009PTC194061] · Manvin Health Private Limited [U52300DL2009PTC189964] · Barfani Baba Pharma Private Limited [U52602DL2009PTC192681] · Amos Biosciences Private Limited [U52310DL2009PTC189924] · D. P. Towers Private Limited [U45201DL1987PTC027884] ·
Vivaar Exim Private Limited
[U24233DL2013PTC247115] |
MAJOR SHAREHOLDERS / SHAREHOLDING PATTERN
AS ON 20.09.2013
|
Names of Shareholders |
|
No. of Shares |
|
Arviv Lifesciences Private Limited, India |
|
1344684 |
|
Ashish Pruthi |
|
900 |
|
Radhika Pruthi |
|
500 |
|
Manvin Heath Private Limited, India |
|
1343184 |
|
Barfani Baba Pharma Private Limited, India |
|
2583397 |
|
Ashish Pruthi & Sons (HUF) |
|
100 |
|
Meera Pruthi |
|
3000 |
|
|
|
|
|
Total |
|
5275765 |
FINANCIAL DATA
[all figures are
in Rupees Millions]
ABRIDGED BALANCE
SHEET
|
SOURCES OF FUNDS |
31.03.2013 |
31.03.2012 |
31.03.2011 |
|
I.
EQUITY
AND LIABILITIES |
|
|
|
|
(1)Shareholders' Funds |
|
|
|
|
(a) Share Capital |
52.758 |
52.758 |
52.758 |
|
(b) Reserves & Surplus |
303.470 |
240.484 |
177.484 |
|
(c) Money
received against share warrants |
0.000 |
0.000 |
0.000 |
|
|
|
|
|
|
(2) Share Application money pending allotment |
0.000 |
0.000 |
0.000 |
|
Total
Shareholders’ Funds (1) + (2) |
356.228 |
293.242 |
230.242 |
|
|
|
|
|
|
(3)
Non-Current Liabilities |
|
|
|
|
(a) long-term borrowings |
38.954 |
6.500 |
3.642 |
|
(b) Deferred tax liabilities (Net) |
12.813 |
0.000 |
0.000 |
|
(c) Other long term liabilities |
0.864 |
2.963 |
0.775 |
|
(d) long-term provisions |
4.959 |
2.814 |
0.000 |
|
Total Non-current Liabilities (3) |
57.590 |
12.277 |
4.417 |
|
|
|
|
|
|
(4) Current Liabilities |
|
|
|
|
(a) Short term
borrowings |
163.964 |
145.873 |
63.385 |
|
(b) Trade payables |
29.429 |
7.868 |
26.535 |
|
(c) Other current
liabilities |
72.503 |
33.995 |
11.157 |
|
(d) Short-term provisions |
8.632 |
13.496 |
13.468 |
|
Total Current Liabilities (4) |
274.528 |
201.232 |
114.545 |
|
|
|
|
|
|
TOTAL |
688.346 |
506.751 |
349.204 |
|
|
|
|
|
|
II. ASSETS |
|
|
|
|
(1) Non-current assets |
|
|
|
|
(a) Fixed Assets |
|
|
|
|
(i) Tangible assets |
270.376 |
104.118 |
78.748 |
|
(ii) Intangible Assets |
0.000 |
0.000 |
0.000 |
|
(iii) Capital
work-in-progress |
31.611 |
41.481 |
23.321 |
|
(iv)
Intangible assets under development |
0.000 |
0.000 |
0.000 |
|
(b) Non-current Investments |
0.000 |
0.000 |
0.000 |
|
(c) Deferred tax assets (net) |
0.000 |
1.005 |
1.536 |
|
(d) Long-term Loan and Advances |
8.675 |
35.470 |
7.852 |
|
(e) Other Non-current assets |
9.314 |
19.769 |
18.970 |
|
Total Non-Current Assets |
319.976 |
201.843 |
130.427 |
|
|
|
|
|
|
(2) Current assets |
|
|
|
|
(a) Current investments |
0.000 |
0.000 |
0.000 |
|
(b) Inventories |
128.586 |
98.951 |
67.564 |
|
(c) Trade receivables |
179.799 |
174.804 |
84.904 |
|
(d) Cash and cash
equivalents |
29.151 |
20.455 |
33.501 |
|
(e) Short-term loans
and advances |
30.834 |
10.698 |
32.808 |
|
(f) Other current
assets |
0.000 |
0.000 |
0.000 |
|
Total Current Assets |
368.370 |
304.908 |
218.777 |
|
|
|
|
|
|
TOTAL |
688.346 |
506.751 |
349.204 |
PROFIT & LOSS
ACCOUNT
|
|
PARTICULARS |
31.03.2013 |
31.03.2012 |
31.03.2011 |
|
|
|
SALES |
|
|
|
|
|
|
|
Revenue from operations |
1115.877 |
920.163 |
784.657 |
|
|
|
Other Income |
8.559 |
3.083 |
2.650 |
|
|
|
TOTAL (A) |
1124.436 |
923.246 |
787.307 |
|
|
|
|
|
|
|
|
Less |
EXPENSES |
|
|
|
|
|
|
|
Cost of materials consumed |
668.259 |
662.930 |
554.933 |
|
|
|
Purchases of stock-in-trade |
96.724 |
9.302 |
6.792 |
|
|
|
Changes in inventories
of finished goods, work-in-progress and stock-in-trade |
(27.835) |
(21.949) |
(22.407) |
|
|
|
Employee benefit expense |
21.769 |
16.408 |
17.255 |
|
|
|
Other expenses |
226.431 |
145.126 |
131.107 |
|
|
|
Prior period items |
1.680 |
0.507 |
0.871 |
|
|
|
TOTAL (B) |
987.028 |
812.324 |
688.551 |
|
|
|
|
|
|
|
|
Less |
PROFIT
BEFORE INTEREST, TAX, DEPRECIATION AND AMORTISATION (A-B) (C) |
137.408 |
110.922 |
98.756 |
|
|
|
|
|
|
|
|
|
Less |
FINANCIAL
EXPENSES (D) |
29.987 |
14.170 |
6.647 |
|
|
|
|
|
|
|
|
|
|
PROFIT
BEFORE TAX, DEPRECIATION AND AMORTISATION (C-D) (E) |
107.421 |
96.752 |
92.109 |
|
|
|
|
|
|
|
|
|
Less/ Add |
DEPRECIATION/
AMORTISATION (F) |
14.538 |
9.943 |
8.367 |
|
|
|
|
|
|
|
|
|
|
PROFIT BEFORE
TAX (E-F) (G) |
92.883 |
86.809 |
83.742 |
|
|
|
|
|
|
|
|
|
Less |
TAX (H) |
33.225 |
23.183 |
21.222 |
|
|
|
|
|
|
|
|
|
|
PROFIT AFTER TAX
(G-H) (I) |
59.658 |
63.626 |
62.520 |
|
|
|
|
|
|
|
|
|
|
EARNINGS IN
FOREIGN CURRENCY |
|
|
|
|
|
|
|
Export Earnings |
299.954 |
169.166 |
124.224 |
|
|
|
|
|
|
|
|
|
Earnings Per
Share (Rs.) |
11.31 |
12.06 |
11.85 |
|
COMPANIES
BACKGROUND
Subject is a limited company domiciled in India and incorporated under
the provisions of the Companies Act, 1956. The company is engaged in
Manufacturing of Bulk Drugs and Manufacturing cum trading of Herbal Products.
MANAGEMENT OVERVIEW
· Sales and Exports
The company has recorded sales revenue and other income of
Rs. 1124.436 Millions against Rs. 923.246 Millions in the previous year. It
represents a growth of 21.79% over preceding year. Further the company has registered
an export of Rs. 299.954 Millions as compared to Rs. 169.166 Millions in the previous
year registering a growth of 77.31% over preceding years. The Management’s
aggressive strategy of focusing on improving business and operational
performance has borne fruits. The operations of the company are steadily
improving and company is looking forward to healthy revenue and numbers profit
in the coming years.
· Profitability
The company earned Profit before tax of Rs. 92.883 Millions against Rs. 86.809 Millions earned in the previous financial year. After providing for taxation of Rs. 33.225 Millions (previous year Rs. 22.653 Millions), net profit worked out to Rs. 59.658 Millions as compared to Rs. 63.626 Millions in the previous year. The company is steadily moving on high growth trajectory and shall continue its journey of profitable growth.
INFRASTRUCTURE
EXPANSION
During the year, the company took an expansion project and modernisation of existing facilities in tandem with its growth plans:
· Expansion at
Bhiwadi Plant
The Company has successfully completed the formulation
project of Rs. 75.000 Millions, for which a Term Loan of Rs. 48.800 Millions
has been arranged from the Banks. The commercial production of the formulation
plant has already been started. Directors are on the opinion that sale and
profits of the company will tremendously increased with the implementation of
the formulation plant.
RATING & COMMENTS
|
MIRA’s Rating : |
Ba (48) |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
Status : |
Satisfactory |
|
|
|
|
Payment Behaviour : |
Usually Correct |
|
|
|
|
Litigation : |
Clear |
RBI DEFAILTERS’ LIST STATUS
Subject’s name is not enlisted as a defaulter
in the publicly available RBI Defaulters’ list.
LOCATIONS
|
Registered Office : |
M-134, 2nd Floor, Opposite Super Bazaar, Connaught Circus, New Delhi –
110001, India |
|
Tel. No.: |
91-11-43561740/ 41/ 42/ 47666106/ 47666111/ 26616318 |
|
Fax No.: |
91-11-43561743 |
|
E-Mail : |
|
|
Website : |
|
|
|
|
|
Corporate Office : |
M-39, Connaught Circus, New Delhi – 110001, India |
|
|
|
|
Factory : |
Plot A-619 and 630, RICO Industrial Area, Bhiwadi – 301019, District
Alwar, Rajasthan, India |
|
Tel No.: |
91-1493-222278/ 512251/ 512378 |
This report is issued at your request without any
risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL)
or its officials.